AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a Phase III open-label trial of its CGRP receptor antagonist, Aquipta/Qulipta (atogepant), for the prevention of migraines in patients with chronic or episodic migraine. The data, collected between weeks 13 to 16, indicated that the average number of monthly migraine days improved by 8.5 days. Notably, 70% of patients in the trial achieved a reduction of 50% or more in their monthly migraine days.
The safety data from the trial was found to be consistent with the known safety profile of the oral drug, with no new safety signals identified. Aquipta/Qulipta is currently approved for the prevention of episodic or chronic migraine in adults who experience four or more monthly migraine days.- Flcube.com
